12-week chronic study GLP-1-H24-4 (the "Study") underway in Australia. Lexaria has completed its submission to the human research ethics committee ("HREC") for its planned addition of Study Arm 5 ...

Arms 2 and 3 of the Study are using DehydraTECH-processed pure semaglutide and will be compared to Study Arm 4 which will use Rybelsus ... In its first-ever GLP-1 study in humans reported ...

Arms 2 and 3 of the Study are using DehydraTECH-processed pure semaglutide and will ... for Human Pilot Study #3 (GLP-1-H24-3). In addition, the Company is pleased to report that it has received HREC ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

"Adherence improves when treatment integrates easily into patients’ lives," explains Adam McBride, Eden’s CEO. Eden’s digital ...

Katz, M.D., of the John A. Moran Eye Center at University of Utah Health, saw a patient who experienced sudden painless vision loss after starting semaglutide. The patient stopped using the drug ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk ... Novo stopped a phase 3b trial of semaglutide, the active ingredient in Ozempic, early for efficacy in October 2023 and ...

It also studies the dual gastric inhibitory polypeptide receptor–GLP-1 RAs labeled for both obesity and T2D (liraglutide, semaglutide ... and 1.4% were on antiobesity medications.